CA2806471C - Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic - Google Patents

Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic Download PDF

Info

Publication number
CA2806471C
CA2806471C CA2806471A CA2806471A CA2806471C CA 2806471 C CA2806471 C CA 2806471C CA 2806471 A CA2806471 A CA 2806471A CA 2806471 A CA2806471 A CA 2806471A CA 2806471 C CA2806471 C CA 2806471C
Authority
CA
Canada
Prior art keywords
peptide
asicalgine
pain
analgesic
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2806471A
Other languages
English (en)
French (fr)
Other versions
CA2806471A1 (fr
Inventor
Eric Lingueglia
Sylvie Diochot
Anne Baron-Forster
Miguel Salinas
Michel Lazdunski
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CA2806471A1 publication Critical patent/CA2806471A1/fr
Application granted granted Critical
Publication of CA2806471C publication Critical patent/CA2806471C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2806471A 2010-07-26 2011-07-26 Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic Active CA2806471C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1003136 2010-07-26
FR1003136A FR2963010B1 (fr) 2010-07-26 2010-07-26 Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic
PCT/FR2011/051800 WO2012022894A1 (fr) 2010-07-26 2011-07-26 Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic

Publications (2)

Publication Number Publication Date
CA2806471A1 CA2806471A1 (fr) 2012-02-23
CA2806471C true CA2806471C (fr) 2020-07-07

Family

ID=43589927

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2806471A Active CA2806471C (fr) 2010-07-26 2011-07-26 Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic

Country Status (13)

Country Link
US (1) US8987207B2 (OSRAM)
EP (1) EP2598523B1 (OSRAM)
JP (1) JP6000245B2 (OSRAM)
CN (1) CN103097404B (OSRAM)
AU (1) AU2011290589A1 (OSRAM)
BR (1) BR112013001863A2 (OSRAM)
CA (1) CA2806471C (OSRAM)
FR (1) FR2963010B1 (OSRAM)
MX (1) MX336586B (OSRAM)
RU (1) RU2583299C2 (OSRAM)
SG (1) SG187877A1 (OSRAM)
WO (1) WO2012022894A1 (OSRAM)
ZA (1) ZA201300662B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105412932B (zh) * 2015-10-26 2019-08-16 上海交通大学医学院 含ASIC1a与RIP1结合抑制剂的制剂及其抑制神经元死亡的用途
CN112618722A (zh) * 2016-11-22 2021-04-09 上海交通大学医学院 酸敏感离子通道调控剂的用途
CN107384952A (zh) * 2017-08-23 2017-11-24 湖南甲骨文生物医药有限公司 用于筛选ASICs作用蛋白的酵母双杂交诱饵载体的构建方法
CN114729034B (zh) * 2019-06-04 2024-01-12 上海科技大学 亲和力成熟的抗ASIC1a抗体
RU2768484C1 (ru) * 2021-05-24 2022-03-24 Закрытое акционерное общество "СКАЙ ЛТД" Фармацевтическая композиция иммуностимулирующих веществ мурамилпептидной природы

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776896A (en) 1996-01-03 1998-07-07 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
JP4959226B2 (ja) * 2006-05-19 2012-06-20 独立行政法人産業技術総合研究所 スリーフィンガー様蛋白質ライブラリ
JP2008193923A (ja) * 2007-02-09 2008-08-28 Janusys Kk 蛋白質ライブラリ

Also Published As

Publication number Publication date
SG187877A1 (en) 2013-03-28
EP2598523A1 (fr) 2013-06-05
CA2806471A1 (fr) 2012-02-23
ZA201300662B (en) 2013-09-25
FR2963010B1 (fr) 2014-08-15
AU2011290589A1 (en) 2013-03-07
US20130196923A1 (en) 2013-08-01
RU2013108262A (ru) 2014-09-10
CN103097404B (zh) 2015-09-16
JP2013535965A (ja) 2013-09-19
MX2013001020A (es) 2014-04-14
MX336586B (es) 2016-01-21
RU2583299C2 (ru) 2016-05-10
US8987207B2 (en) 2015-03-24
WO2012022894A4 (fr) 2012-04-12
FR2963010A1 (fr) 2012-01-27
WO2012022894A1 (fr) 2012-02-23
EP2598523B1 (fr) 2015-09-09
JP6000245B2 (ja) 2016-09-28
CN103097404A (zh) 2013-05-08
BR112013001863A2 (pt) 2016-05-31

Similar Documents

Publication Publication Date Title
CA2832521C (fr) Peptides therapeutiques et leur utilisation contre la choree de huntington
EP2598523B1 (fr) Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic
JP5918750B2 (ja) Ｔｒｅｍ様転写物１（ｔｌｔ−１）から誘導された阻害性ペプチドおよびその使用
EP0648269A1 (fr) Nouveaux polypeptides ayant une activite de recepteur nmda, acides nucleiques codant pour ces polypeptides et utilisations
Osipov et al. Snake venom toxins targeted at the nervous system
Perazzo et al. Pharmacological potential of the endogenous dipeptide kyotorphin and selected derivatives
EP2300043B1 (fr) Effets analgesiques de la toxine peptidique apetx2
Xu et al. NaV1. 7 channel blocker [Ala5, Phe6, Leu26, Arg28] GpTx-1 attenuates CFA-induced inflammatory hypersensitivity in rats via endogenous enkephalin mechanism
US9109041B2 (en) Analog compounds of analgesic peptides derived from the venom of crotalus durissus terrificus snakes, their uses, compositions, methods of preparation and purification
CA2749824C (fr) Identification de nouvelles toxines antagonistes de canaux calciques type-t a visee analgesique
US10894811B2 (en) Peptide inhibitors of calcium channels
EP4225295B1 (fr) Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique
Ward et al. Conotoxins: A Pharmacological Arsenal Yet to be Fully Explored
White et al. Kinases and Their Potential as Therapeutic Targets in Huntington’s Disease
FR2701265A1 (fr) Nouveaux polypeptides ayant une activité de récepteur sérotoninergique, acides nucléiques codant pour ces polypeptides et utilisations.
Alsaleh et al. BAFF synthesis by rheumatoid synoviocytes is positively controled by integrin α5β1 stimulation and negatively regulated by TNFα and TLR ligands
Veglianese Sub-cellular localization and regulatory mechanisms of AMPA receptors in motor neurons of a murine model of familial Amyotrophic Lateral Sclerosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160527

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240724

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250723

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250925